Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer
Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer
复制标题
DOI：
10.1159/000120627
复制
发表时间：
2007-01-01
期刊：
影响因子：
3.5
通讯作者：
Van Laethem, J. L.
中科院分区：
文献类型：
--
作者：
Marechal, R.;Demols, A.;Van Laethem, J. L.
背景：吉西他滨单药治疗是晚期胰腺癌（PC）患者治疗的基石。几年来，新的化学治疗剂和组合一直在验证中。这种治疗的使用使得有必要确定可以预测生存时间的因素。患者和方法：为了确定预测化疗未治晚期PC患者和吉西他滨治疗失败后生存时间的因素，对来自II期和III期研究并接受基于吉西他滨的一线化疗的晚期PC患者进行了回顾性分析。结果如下：99例患者（中位年龄66岁，范围27-87）患有病理证实的不可切除或转移性胰腺腺癌进行了审查。整个人群的中位总生存时间为251天，一线和二线治疗的无进展生存期分别为108天和67天。考克斯回归分析确定天冬氨酸转氨酶1 53 IU/l，体重减轻>= 10%和Karnofsky体能状态！90作为一线和CA 19-9 > 400 IU/ml和白蛋白的显著独立阴性预后因素
Background: Gemcitabine monotherapy is the cornerstone of the treatment of patients suffering from advanced pancreatic cancer (PC). For a few years, new chemotherapeutic agents and combinations have been under validation. The use of such treatment makes it necessary to determine factors that could predict survival time. Patients and Methods: To identify factors that predict survival time in chemonaive patients with advanced PC and after gemcitabine failure, a retrospective analysis was performed on patients with advanced PC coming from phase II and III studies and treated with gemcitabine-based first-line chemotherapy. Results: Ninety-nine patients (median age 66 years, range 27-87) suffering from pathologically proven unresectable or metastatic adenocarcinoma of the pancreas were reviewed. Median overall survival time for the whole population was 251 days and progression-free survival in first- and second-line treatment was 108 and 67 days, respectively. The Cox regression analysis identified aspartate transaminase 1 53 IU/l, weight loss >= 10% and Karnofsky performance status ! 90 as significant independent negative prognostic factors in first- line and CA 19-9 > 400 IU/ml and albumin